Leap Therapeutics (NASDAQ:LPTX) Receives “Buy” Rating from HC Wainwright

Leap Therapeutics (NASDAQ:LPTX)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a research note issued on Thursday,Benzinga reports. They presently have a $5.50 target price on the stock. HC Wainwright’s target price suggests a potential upside of 69.23% from the stock’s current price.

Leap Therapeutics Trading Up 5.2 %

NASDAQ LPTX opened at $3.25 on Thursday. Leap Therapeutics has a 12 month low of $1.68 and a 12 month high of $4.79. The company’s 50-day moving average price is $3.01 and its 200-day moving average price is $2.75. The stock has a market cap of $124.54 million, a PE ratio of -1.68 and a beta of 0.17.

Institutional Trading of Leap Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of LPTX. Valence8 US LP bought a new position in Leap Therapeutics in the third quarter worth approximately $48,000. HighTower Advisors LLC purchased a new stake in shares of Leap Therapeutics in the 3rd quarter worth $65,000. HB Wealth Management LLC grew its position in shares of Leap Therapeutics by 103.2% during the 4th quarter. HB Wealth Management LLC now owns 51,500 shares of the company’s stock worth $150,000 after buying an additional 26,150 shares in the last quarter. Key Client Fiduciary Advisors LLC increased its stake in shares of Leap Therapeutics by 13.0% during the third quarter. Key Client Fiduciary Advisors LLC now owns 321,923 shares of the company’s stock valued at $827,000 after buying an additional 37,067 shares during the period. Finally, Geode Capital Management LLC raised its holdings in shares of Leap Therapeutics by 18.0% in the third quarter. Geode Capital Management LLC now owns 329,291 shares of the company’s stock valued at $847,000 after acquiring an additional 50,194 shares in the last quarter. Institutional investors own 30.46% of the company’s stock.

Leap Therapeutics Company Profile

Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501.